Eli Lilly Agrees to Acquire Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly announced it will acquire privately held Ajax Therapeutics for up to $2.3 billion in cash to strengthen its blood cancer treatment portfolio. The deal focuses on Ajax's lead experimental drug for myelofibrosis, a rare chronic blood cancer. It includes an upfront payment and potential milestone payments tied to clinical and regulatory achievements.
insidermonkey.comEli Lilly has agreed to purchase Ajax Therapeutics, a privately held developer of blood cancer treatments, for up to $2.3 billion in cash. The acquisition aims to bolster Lilly's oncology pipeline, particularly in treatments for myelofibrosis. All sources confirmed the deal value and structure, which includes an upfront payment followed by additional payments upon reaching specific clinical and regulatory milestones.
Ajax's lead asset, AJ1-11095, is an experimental once-daily oral treatment currently in early-stage testing for patients with myelofibrosis who have undergone prior treatment. Myelofibrosis is a rare, chronic blood cancer characterized by scar tissue buildup in the bone marrow, which disrupts normal blood cell production.
The deal aligns with Lilly's recent efforts to expand its blood cancer offerings. Jacob Van Naarden, president of Lilly Oncology, highlighted the company's intent to advance the drug rapidly. " — Jacob Van Naarden, president of Lilly Oncology (CNBC).
Lilly plans to present clinical proof-of-concept data for AJ1-11095 later in 2026. The company aims to move the treatment into registrational clinical trials following that milestone.
The total deal value of up to $2.3 billion encompasses payments contingent on achieving certain development goals. Sources described Ajax's AJ1-11095 as a Phase 1 JAK2 inhibitor specifically targeted at myelofibrosis. This acquisition follows Lilly's pattern of investing in oncology assets to enhance its portfolio.
No contradictions appeared across the sources regarding the deal's terms or the drug's description.
affects blood cell production due to bone marrow scarring, leading to symptoms like anemia and fatigue. Current treatments vary, but Ajax's oral option represents a potential new approach for patients who have not responded to prior therapies. Lilly's oncology division has experience in developing blood cancer drugs, which it plans to leverage for AJ1-11095's advancement.
The deal was announced on Monday, with sources providing consistent details on the asset's early-stage status.
Key Facts
Story Timeline
2 events- Today
Eli Lilly announced the acquisition of Ajax Therapeutics for up to $2.3 billion.
4 sourcesCNBC · Seeking Alpha · WSJ - Later in 2026
Planned presentation of clinical proof-of-concept data for AJ1-11095.
2 sourcesCNBC
Potential Impact
- 01
Lilly's oncology pipeline will expand with a new Phase 1 asset for blood cancers.
- 02
Ajax's AJ1-11095 will advance to registrational trials post-2026 data.
- 03
Patients with myelofibrosis may gain access to a new oral treatment option.
- 04
Lilly could achieve regulatory milestones triggering additional payments.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…